Livneh A, Zemer D, Langevitz P, Shemer J, Sohar E, Pras M
Heller Institute of Medical Research, Sheba Medical Center, Tel Hashomer, Israel.
Semin Arthritis Rheum. 1993 Dec;23(3):206-14. doi: 10.1016/s0049-0172(05)80042-3.
Colchicine is an effective medication in the prevention and treatment of amyloidosis of familial Mediterranean fever. Its therapeutic effect depends on the stage of renal disease and the drug dose. To evaluate colchicine effect in AA amyloidosis of other diseases and in primary AL amyloidosis, the literature was reviewed. Findings were that (1) the effect of colchicine in reactive amyloidosis has not been methodically studied, but anecdotal reports suggest it may be beneficial; and (2) the results of studies and case reports on the effect of colchicine in primary amyloidosis are conflicting. Because a therapeutic effect of colchicine in primary and reactive amyloidosis has been shown in sporadic cases, a prospective, controlled, multicenter study assessing the effect of colchicine in all types of amyloidosis appears to be justified. Until such a study is available, the addition of colchicine in an appropriate dose to any therapeutic regimen of patients with AA or AL amyloidosis should be considered.
秋水仙碱是预防和治疗家族性地中海热淀粉样变性的有效药物。其治疗效果取决于肾脏疾病的阶段和药物剂量。为了评估秋水仙碱在其他疾病的AA淀粉样变性和原发性AL淀粉样变性中的作用,对相关文献进行了综述。结果发现:(1)秋水仙碱在反应性淀粉样变性中的作用尚未得到系统研究,但轶事报道表明它可能有益;(2)关于秋水仙碱在原发性淀粉样变性中作用的研究和病例报告结果相互矛盾。由于在散发病例中已显示秋水仙碱对原发性和反应性淀粉样变性有治疗作用,因此开展一项评估秋水仙碱在所有类型淀粉样变性中作用的前瞻性、对照、多中心研究似乎是合理的。在有这样的研究之前,应考虑在AA或AL淀粉样变性患者的任何治疗方案中添加适当剂量的秋水仙碱。